Skip to main content
. 2015 Feb 20;308(8):L776–L787. doi: 10.1152/ajplung.00334.2014

Fig. 2.

Fig. 2.

Effects of LPS and 17-allyl-amino-demethoxy-geldanamycin (17-AAG) on p53 and p21 expression in HLMVEC. A: Western blot analysis of p53 levels in HLMVEC after 2 h treatment with vehicle or LPS. Blot shown is representative of 3 independent experiments. Signal intensity of p53 was analyzed by densitometry. Protein levels were normalized to β-actin. **P < 0.01 vs. vehicle. Means ± SE. B: Western blot analysis of p53 levels in HLMVEC after 4 h or 16 h treatment with 17-AAG; 10% DMSO was used as vehicle. Signal intensity of p53 was analyzed by densitometry. Protein levels were normalized to β-actin. ***P < 0.001 vs. vehicle. Means ± SE. C: Western blot analysis of p21 levels in HLMVEC after 2 h treatment with vehicle or LPS. Blot shown is representative of 3 independent experiments. Signal intensity of p21 was analyzed by densitometry. Protein levels were normalized to β-actin. *P < 0.05 vs. vehicle. Means ± SE. D: Western blot analysis of p21 levels in HLMVEC after 8 h treatment with either vehicle (10% DMSO) or 17-AAG. Signal intensity of p21 was analyzed by densitometry. Protein levels were normalized to β-actin. **P < 0.01 vs. vehicle. Means ± SE.